CanSino Biologics Inc. CASBF
3.41 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
3.41 Day range 3.55
2.60 52-week range 5.60
- YTD
- -28.06%
- 1 year
- -39.11%
News
prnewswire.com CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026…
youtube.com CanSino Biologics CEO on earnings, business outlook, and international partnerships Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the…
seekingalpha.com Riding Covid Vaccine Highs, CanSino Plans Swiss Listing After successful listings in Shanghai and Hong Kong, vaccine maker CanSino is preparing to move into Europe with a listing in Switzerland. Sales could surge for the company's Covid-19 vaccines as…
investorplace.com Why Is CanSino Biologics (CASBF) Stock Soaring Today? CanSino Biologics (OTCMKTS: CASBF ) are ripping higher on Wednesday, with CASBF stock up about 75% on the day. The move is startling, particularly given the poor price action we were seeing in the…
reuters.com China's CanSinoBIO H1 revenue drops on weaker COVID shot demand China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots.
reuters.com COVID shot drives CanSinoBIO's first six-month profit since at least 2019 Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of…
seekingalpha.com Pandemic Accelerates China's Drive Into mRNA Treatments Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese…